u/DeepForumResearch

So it was recently brought to my attention that a Bangladesh-based pharmaceutical company called Square Pharmaceuticals makes a generic amenamevir. As far as I'm aware, Maruho (the makers of amenamevir) was granted a patent extension and amenamevir is still under patent.

Apparently Bangladesh has what's a called a "Least Developed Country" status which allows it to bypass pharmaceutical patent enforcements until 2033. They're able to make generic HIV drugs that are used all over the world. So once pritelivir is approved, if a Bangladeshi pharmaceutical company like Square understood the demand for pritelivir was high, they would likely start to make it.

As crazy as it sounds, I think the best form of "activism" would be to reach out to Bangladeshi generic pharma manufacturers and explain to them what pritelivir is and why they should make it. Then medical tourism to obtain it or buying it from online pharmacies actually becomes possible.

The FDA isn't going to help us here.

reddit.com
u/DeepForumResearch — 1 month ago

There have been several studies published in the past year showing amenamevir being highly effective in acyclovir-resistant cases of HSV.

While we don't have any real shedding data on amenamevir, it is clearly an effective medication against HSV1 and 2.

I know some people have reported it didn't help them. But these case reports show that it clearly can be effective.

Some of the papers are paywalled but I was able to access them through a subscription I have.

Amenamevir for acyclovir-resistant genital HSV-2 infection in people living with HIV

>

Use of short-course oral amenamevir (helicase-primase inhibitor) for the treatment of thymidine analogue-resistant herpes simplex lesions

>

>

Successful treatment of acyclovir-resistant herpes simplex virus infection with amenamevir in a patient who received umbilical cord blood transplantation for T-cell prolymphocytic leukemia

>

Efficacy and Safety of Amenamevir, a Helicase-Primase Inhibitor for the Treatment of Acyclovir-Resistant Herpes Simplex Virus 1 Keratitis

86 percent reduction in HSK recurrences. No adverse events reported over 6 patients who took amenamevir at 200 mg daily for 16 months on average.

>

reddit.com
u/DeepForumResearch — 1 month ago